The American Society of Retina Specialists (ASRS) reported six cases of occlusive retinal vasculitis post pegcetacoplan injection. The etiology remains unclear, with evolving patient outcomes. Pegcetacoplan, targeting complement factor 3 in drusen, was approved for geographic atrophy treatment. Trials showed low rates of intraocular inflammation but no retinal vasculitis. Apellis Pharmaceuticals is investigating the cases, emphasizing the importance of sterile practices during injection.
toiselle kielelle
lähdeaineistosta
www.medscape.com
Tärkeimmät oivallukset
by Richard Mark... klo www.medscape.com 07-18-2023
https://www.medscape.com/viewarticle/994508Syvällisempiä Kysymyksiä